|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable, net of allowance of $75 and $50, respectively | ||||||||||||||||||||
| Note receivable | ||||||||||||||||||||
| Current licensing fees receivable | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Prefunded insurance premiums from financing | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Deferred financing costs | ||||||||||||||||||||
| Current assets of discontinued operations | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Long-term note receivable | ||||||||||||||||||||
| Long-term licensing fees receivable | ||||||||||||||||||||
| Fixed assets, net of accumulated depreciation of $754 and $583, respectively | ||||||||||||||||||||
| Non-current assets of discontinued operations | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Line of credit | ||||||||||||||||||||
| Revolving credit facility and loans | ||||||||||||||||||||
| Insurance premium financing | ||||||||||||||||||||
| Taxes payable | ||||||||||||||||||||
| Promissory notes | ||||||||||||||||||||
| Current liabilities of discontinued operations | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Common stock, no par value:Authorized — 800,000,000. Issued and outstanding shares — 118,780,917 shares and 118,227,478 shares, respectively | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...